
What is claimed is:

1. A compound according to Formula (I):



(I)

wherein:

R^1 is H, -SO_2(C_1-C_4alkyl), -CO(C_1-C_4alkyl), or (C_1-C_4alkyl);

R^2 is -SOR^a or -SO_2R^a, wherein R^a is an optionally substituted (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl group, wherein:

said (C_1-C_6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, (C_1-C_6)alkoxy, (C_1-C_6)alkoxy(C_2-C_6)alkoxy, -CO_2H, -CO_2(C_1-C_4)alkyl, -SO_2(C_1-C_4 alkyl), -$CONH_2$, -CONH(C_1-C_4 alkyl), -NHC(=O)(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C(=O)(C_1-C_4 alkyl)), -SO_2NH_2, -SO_2NH(C_1-C_4 alkyl), -$NHSO_2$(C_1-C_4 alkyl), -SO_2N(C_1-C_4 alkyl)(C_1-C_4 alkyl), - N(C_1-C_4 alkyl)(SO_2(C_1-C_4 alkyl)), amino, (C_1-C_4 alkyl)amino-, (C_1-C_4 alkyl)(C_1-C_4 alkyl)amino-, C_3-C_7cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and (phenyl)(C_1-C_4 alkyl)amino-, wherein said C_3-C_7cycloalkyl, phenyl, (phenyl)(C_1-C_4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl, hydroxy(C_1-C_4)alkyl and (C_1-C_4)alkoxy,

said (C_3-C_7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF_3, hydroxyl, amino, (C_1-C_4 alkyl)amino-, (C_1-C_4 alkyl)(C_1-C_4 alkyl)amino-, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl-, oxo, (C_1-C_4)alkoxy, and (C_1-C_4)alkoxy(C_2-C_4)alkoxy-, and

said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF_3, hydroxyl, amino, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl- and (C_1-C_4)alkoxy,

and wherein said heteroaryl is a 5-6 membered heteroaryl or a 9-10 membered heteroaryl, and any of said 4-7 membered heterocycloalkyl contains one heteroatom selected from the group

consisting of N, O and S, any of said 5-6 membered heteroaryl contains one heteroatom selected from the group consisting of N, O and S and optionally further containing one or two nitrogen atoms, and any of said 9-10 membered heteroaryl contains one heteroatom selected from the group consisting of N, O and S and optionally further containing 1, 2 or 3 nitrogen atoms;

R^3 is halogen, hydroxy, (C_1-C_4)alkyl-, (C_1-C_4)alkoxy-, halo(C_1-C_4)alkyl-, halo(C_1-C_4)alkoxy-, (C_1-C_4)alkoxy(C_1-C_6)alkyl-, halo(C_1-C_4)alkoxy(C_1-C_6)alkyl-, (C_1-C_4)alkoxy(C_2-C_6)alkoxy-, halo(C_1-C_4)alkoxy(C_2-C_6)alkoxy-, hydroxy(C_1-C_4)alkyl-, hydroxy(C_2-C_6)alkoxy-, cyano(C_1-C_4)alkyl-, cyano(C_2-C_6)alkoxy-, or (C_3-C_6)cycloalkoxy-, wherein the halo(C_1-C_4)alkyl-, halo(C_1-C_4)alkoxy-, halo(C_1-C_4)alkoxy(C_1-C_6)alkyl-, or halo(C_1-C_4)alkoxy(C_2-C_6)alkoxy- contains 2 or 3 halo atoms and wherein the (C_3-C_6)cycloalkyl moiety of the (C_3-C_6)cycloalkoxy- group, is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (C_1-C_6)alkoxy and (C_1-C_4)alkoxy(C_2-C_6)alkoxy;

Z is phenyl or aryl(C_1-C_4)alkyl-, substituted by R^4, R^5, R^6 and R^7, wherein:

R^4 is H, halogen, cyano, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C_1-C_4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy; and


each of R^5, R^6 and $R^7$is independently selected from the group consisting of H, hydroxyl, halogen, -CF_3, hydroxy(C_1-C_4)alkyl, (C_1-C_4)alkyl and (C_1-C_4)alkoxy; or

Z is phenyl substituted by R^8, R^9 and R^{10}, wherein:

R^8 and R^9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from the group consisting of N, O and S, which 5-membered heterocyclic group is substituted by R^{11};

wherein one of R^{10} or R^{11} is H, halogen, cyano, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(C_1-C_4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy; and

the other of R^{10} or R^{11} is H, hydroxyl, halogen, halo(C_1-C_4)alkyl, hydroxy(C_1-C_4)alkyl, (C_1-C_4)alkyl or (C_1-C_4)alkoxy; or

Z is pyrazolyl, having the formula:  wherein:

R^{12} is methyl or trifluoromethyl (-CH_3 or -CF_3);

R^{13} is H, methyl, hydroxymethyl, or trifluoromethyl (-CH_3, -CH_2OH or -CF_3);

R^{14} is H or (C_1-C_3)alkyl; or


R^{12} and R^{13}, taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R^{15} and R^{16}, wherein the heterocyclic ring contains 1 nitrogen atom;

wherein R^{15} and R^{16} are each independently selected from the group consisting of H, halogen, cyano, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C_1-C_4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy;

provided that the compound is not N-(4-chloro-2-fluorophenyl)-7-methoxy-6-[(2-methoxyethyl)sulfinyl]-4-quinolinamine or 3-[[7-bromo-6-(methylsulfonyl)-4-quinolinyl]amino]-4-methyl-phenol;

or a salt thereof.

2. The compound or salt according to claim 1, wherein Z is phenyl, having the formula:



wherein:

R^{Z1} is H, halogen, -CF_3, (C_1-C_4)alkyl or (C_1-C_4)alkoxy;

R^{Z2} is H, halogen, -CF_3, (C_1-C_4)alkyl or (C_1-C_4)alkoxy;

R^{Z3} is H, halogen, cyano, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C_1-C_4)alkoxy- is optionally substituted by 1-3 substituents each

independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy; and

R^{Z4} is hydroxyl, hydroxy(C_1-C_4)alkyl or (C_1-C_4)alkoxy.

3. The compound or salt according to claim 1, wherein Z is 3-methoxy-4-chloro-phenyl or 2-methyl-5-(hydroxymethyl)-phenyl.

4. The compound or salt according to claim 1, wherein Z is benzothiazolyl, optionally substituted by 1or 2 substituents each independently selected from the group consisting of halogen, (C_1-C_4)alkyl, -CF_3, and (C_1-C_4)alkoxy.

5. The compound or salt according to claim 1, wherein Z is benzothiazol-6-yl.

6. The compound or salt according to claim 1, wherein Z is pyrazolyl, R^{12} is methyl or trifluoromethyl, R^{13} is H, methyl, or trifluoromethyl, and R^{14} is H or methyl.

7. The compound or salt according to claim 1, wherein Z is pyrazolyl, R^{12} and R^{13} are independently selected from the group consisting of methyl and trifluoromethyl, and R^{14} is H or methyl.

8. The compound or salt according to claim 1, wherein Z is pyrazolyl, R^{12} is methyl, R^{13} is methyl or trifluoromethyl, and R^{14} is H.

9. The compound or salt according to claim 1, wherein Z is pyrazolyl, substituted by R^{12} and R^{13} wherein R^{12} and R^{13} are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 6 membered carbocyclic ring or heterocyclic ring substituted by R^{15} and R^{16};

wherein R^{15} is H, halogen, cyano, (C_1-C_4)alkyl, -CF_3, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C_1-C_4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy; and

R^{16} is H, hydroxyl, halogen, -CF_3, hydroxy(C_1-C_4)alkyl, (C_1-C_4)alkyl or (C_1-C_4)alkoxy.

10. The compound or salt according to claim 1, wherein Z is an optionally substituted indazolyl or pyrazolo[3,4-*b*]pyridinyl group, where the Z group is optionally substituted by 1 or 2 substituents each independently selected from the group consisting of chloro, fluoro, methyl, and methoxy.

11. The compound or salt according to claim 1, wherein Z is 4-chloro-1*H*-indazol-3-yl, 5-chloro-1*H*-indazol-3-yl, 6-chloro-1*H*-indazol-3-yl, 7-chloro-1*H*-indazol-3-yl, 5-fluoro-1*H*-indazol-3-yl, 7-fluoro-1*H*-indazol-3-yl, 5-,7-difluoro-1*H*-indazol-3-yl, 6,7-difluoro-1*H*-indazol-3-yl, 5-methoxy-1*H*-indazol-3-yl or 5-fluoro-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl.

12. The compound or salt according to any one of claims 1-11, wherein R^1 is H.

13. The compound or salt according to any one of claims 1-12, wherein R^2 is $-SOR^a$.

14. The compound or salt according to any one of claims 1-12, wherein R^2 is or $-SO_2R^a$.

15. The compound or salt according to any one of claims 1-14, wherein R^a is $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted by 1or 2 substituents each independently selected from the group consisting of hydroxyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkoxy$(C_2\text{-}C_4)$alkoxy-, amino, $(C_1\text{-}C_4$ alkyl)amino-, $(C_1\text{-}C_4$ alkyl$)(C_1\text{-}C_4$ alkyl)amino-, (phenyl$)(C_1\text{-}C_4$ alkyl)amino-, $-CO_2(C_1\text{-}C_4)$alkyl, $-CONH_2$, $-SO_2(C_1\text{-}C_4)$alkyl, and a $C_3\text{-}C_6$cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl, where said $C_3\text{-}C_6$cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-CF_3$, hydroxyl, amino, $(C_1\text{-}C_4)$alkyl, phenyl$(C_1\text{-}C_4)$alkyl-, hydroxy$(C_1\text{-}C_4)$alkyl- and $(C_1\text{-}C_4)$alkoxy.

16. The compound or salt according to any one of claims 1-14, wherein R^a is $(C_1\text{-}C_4)$alkyl wherein said $(C_1\text{-}C_4)$alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, $(C_1\text{-}C_2)$alkoxy, $(C_1\text{-}C_2)$alkoxy$(C_2\text{-}C_3)$alkoxy-, amino, $(C_1\text{-}C_3$ alkyl)amino-, and $(C_1\text{-}C_3$ alkyl$)(C_1\text{-}C_2$ alkyl)amino-.

17. The compound or salt according to any one of claims 1-14, wherein R^a is C_3-C_6cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl, wherein said C_3-C_6cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF_3, hydroxyl, amino, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl- and (C_1-C_4)alkoxy.

18. The compound or salt according to any one of claims 1-14, wherein R^a is C_3-C_6cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl, wherein:

said C_3-C_6cycloalkyl is optionally substituted by 1or 2 substituents each independently selected from the group consisting of hydroxyl, (C_1-C_4)alkyl, (C_1-C_2)alkoxy, (C_1-C_2)alkoxy(C_2-C_3)alkoxy-, amino, (C_1-C_3 alkyl)amino-, and (C_1-C_3 alkyl)(C_1-C_2 alkyl)amino-,

said 4-6-membered heterocycloalkyl is optionally substituted by 1 or 2 groups independently selected from the group consisting of (C_1-C_4)alkyl or benzyl, wherein the 4-6 membered heterocycloalkyl contains one heteroatom selected from the group consisting of N, O and S,

said 5-6-membered heteroaryl is optionally substituted by (C_1-C_4)alkyl or hydroxy(C_1-C_4)alkyl, wherein the 5-6 membered heteroaryl contains one heteroatom selected from the group consisting of N, O and S or contains one nitrogen atom and a second one heteroatom selected from the group consisting of N, O and S optionally contains additional heteroatom nitrogen atom, and

said phenyl is optionally substituted by amino.

19. The compound or salt according to any one of claims 1-14, wherein R^a is (C_1-C_4)alkyl, tetrahydrofuranyl, tetrahydropyranyl or piperidinyl, wherein:

said (C_1-C_4)alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (C_1-C_2)alkoxy, (C_1-C_2)alkoxy(C_2-C_3)alkoxy-, amino, (C_1-C_3 alkyl)amino-, (C_1-C_3 alkyl)(C_1-C_2 alkyl)amino-, and a C_3-C_6cycloalkyl (optionally substituted by (C_1-C_4)alkyl or hydroxy(C_1-C_4)alkyl), and

said tetrahydrofuranyl, tetrahydropyranyl or piperidinyl is optionally substituted by 1 or 2 groups independently selected from the group consisting of halogen, -CF_3, hydroxyl, amino, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl- and (C_1-C_4)alkoxy.

20. The compound or salt according to any one of claims 1-14, wherein R^a is an unsubstituted (C_1-C_4)alkyl or a (C_1-C_4)alkyl substituted by one substituent selected from the group consisting of hydroxyl, (C_1-C_2)alkoxy, and (C_1-C_2)alkoxy(C_2-C_3)alkoxy-.

21. The compound or salt according to any one of claims 1-14, wherein R^a is tetrahydropyranyl, wherein the tetrahydropyranyl group is optionally substituted by 1 or 2 independently selected (C_1-C_4)alkyl groups.

22. The compound or salt according to any one of claims 1-14, wherein R^a is $-CH_3$, $-CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2CH_2OH$, $-C(CH_3)_2CH_2OH$, $-CH_2CH_2OCH_3$, tetrahydro-2*H*-pyran-4-yl, 2,2-dimethyltetrahydro-2*H*-pyran-4-yl, 4-methyltetrahydro-2*H*-pyran-4-yl, (3R,4R)-3-methyltetrahydro-2*H*-pyran-4-yl, or (2R,6S)-2,6-dimethyltetrahydro-2*H*-pyran-4-yl.

23. The compound or salt according to any one of claims 1-22, wherein R^3 is halogen, hydroxy, (C_1-C_4)alkyl-, halo(C_1-C_4)alkyl-, (C_1-C_4)alkoxy-, halo(C_1-C_4)alkoxy-, (C_1-C_4)alkoxy(C_1-C_6)alkyl-, (C_1-C_4)alkoxy(C_2-C_6)alkoxy-, hydroxy(C_1-C_4)alkyl-, or hydroxy(C_2-C_6)alkoxy-.

24. The compound or salt according to any one of claims 1-22, wherein R^3 is halogen, hydroxy, (C_1-C_3)alkyl-, halo(C_1-C_2)alkyl-, (C_1-C_3)alkoxy-, (C_1-C_3)alkoxy(C_1-C_3)alkyl-, (C_1-C_3)alkoxy(C_2-C_3)alkoxy-, hydroxy(C_1-C_3)alkyl-, or hydroxy(C_2-C_3)alkoxy-.

25. The compound or salt according to any one of claims 1-22, wherein R^3 is chloro, bromo, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, difluoromethoxy, ethoxy, or 2-hydroxyethoxy-.

26. The compound or salt according to any one of claims 1-11, wherein R^1 is H; R^2 is $-SOR^a$, or $-SO_2R^a$, and R^a is (C_1-C_4)alkyl or a 5-6-membered heterocycloalkyl, wherein said (C_1-C_4)alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (C_1-C_2)alkoxy, (C_1-C_2)alkoxy(C_2-C_3)alkoxy-, amino, (C_1-C_3 alkyl)amino-, and (C_1-C_3 alkyl)(C_1-C_2 alkyl)amino-, and said 5-6-membered heterocycloalkyl is optionally substituted by 1 or 2 independently selected (C_1-C_4)alkyl groups, wherein the 5-6 membered

heterocycloalkyl group contains 1 heteroatom selected from the group consisting of N, O and S; and R^3 is halogen, hydroxy, (C_1-C_3)alkyl-, halo(C_1-C_2)alkyl-, (C_1-C_3)alkoxy-, (C_1-C_3)alkoxy(C_1-C_3)alkyl-, (C_1-C_3)alkoxy(C_2-C_3)alkoxy-, hydroxy(C_1-C_3)alkyl-, or hydroxy(C_2-C_3)alkoxy-.

27. The compound or salt according to any one of claims 1-11, wherein R^1 is H; R^2 is -SOR^a, or -SO_2R^a, and R^a is -CH_3, -$CH(CH_3)_2$, -$C(CH_3)_3$, -CH_2CH_2OH, -$C(CH_3)_2CH_2OH$, -$CH_2CH_2OCH_3$, tetrahydro-2*H*-pyran-4-yl, 2,2-dimethyltetrahydro-2*H*-pyran-4-yl, 4-methyltetrahydro-2*H*-pyran-4-yl, (3R,4R)-3-methyltetrahydro-2*H*-pyran-4-yl, or (2R,4S,6S)-2,6-dimethyltetrahydro-2*H*-pyran-4-yl; and R^3 is chloro, bromo, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, difluoromethoxy, ethoxy, or 2-hydroxyethoxy-.

28. A compound which is:

6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxyquinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-(methyloxy)-6-(tetrahydro-2*H*-pyran-4-ylsulfinyl)-4-quinolinamine;

6-[(1,1-dimethylethyl)sulfinyl]-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-(methyloxy)-4-quinolinamine;

2-((4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)-7-methoxyquinolin-6-yl)sulfonyl)-2-methylpropan-1-ol;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

2-((4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)-7-methylquinolin-6-yl)sulfonyl)ethanol;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-((2,2-dimethyltetrahydro-2*H*-pyran-4-yl)sulfonyl)-7-methoxyquinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxy-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxy-6-((2-methoxyethyl)sulfonyl)quinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxy-6-(((3R,4R)-3-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-(4,5-dimethyl-1H-pyrazol-3-yl)-6-(((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)sulfonyl)-7-methoxyquinolin-4-amine;

6-(tert-butylsulfonyl)-N-(5-fluoro-1*H*-pyrazolo[3,4-b]pyridin-3-yl)-7-methoxyquinolin-4-amine;

N-[4-chloro-3-(methyloxy)phenyl]-6-[(1,1-dimethyl ethyl)sulfonyl]-7-(methyloxy)-4-quinolinamine;

N-[4-chloro-3-(methyloxy)phenyl]-7-(methyloxy)-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinolinamine;

N-1,3-benzothiazol-5-yl-7-(methyloxy)-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinolinamine;

2-{[4-{[4-chloro-3-(methyloxy)phenyl] amino}-7-(methyloxy)-6-quinolinyl]sulfonyl}ethanol;

N-(5-fluoro-1*H*-indazol-3-yl)-7-(methyloxy)-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinolinamine;

2-{[4-[(4,5-dimethyl-1*H*-pyrazol-3-yl)amino]-7-(methyloxy)-6-quinolinyl]sulfonyl}ethanol;

N-[4-chloro-3-(methyloxy)phenyl]-6-[(1-methylethyl) sulfonyl]-7-(methyloxy)-4-quinolinamine;

N-1,3-benzothiazol-5-yl-6-[(1-methylethyl) sulfonyl]-7-(methyloxy)-4-quinolinamine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-[(1-methylethyl) sulfonyl]-7-(methyloxy)-4-quinolinamine;

N-(5-fluoro-1*H*-indazol-3-yl)-6-[(1-methylethyl) sulfonyl]-7-(methyloxy)-4-quinolinamine;

2-{[4-(1,3-benzothiazol-5-ylamino)-7-(methyloxy)-6-quinolinyl]sulfonyl}ethanol;

6-(isopropylsulfonyl)-7-methoxy-N-(4-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl)quinolin-4-amine;

6-(tert-butylsulfonyl)-7-methoxy-N-(4-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl)quinolin-4-amine;

6-(*tert*-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-ethoxyquinolin-4-amine;

6-(*tert*-butylsulfonyl)-7-ethoxy-N-(5-fluoro-1*H*-indazol-3-yl)quinolin-4-amine;

7-chloro-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl) sulfonyl)quinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methyl-6-((tetrahydro-2*H*-pyran-4-yl) sulfonyl)quinolin-4-amine;

7-chloro-N-(5-fluoro-1*H*-indazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl) sulfonyl)quinolin-4-amine;

N-(5-fluoro-1*H*-indazol-3-yl)-7-methyl-6-((tetrahydro-2*H*-pyran-4-yl) sulfonyl)quinolin-4-amine;

N-(5-fluoro-1*H*-indazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)-7-(trifluoromethyl) quinolin-4-amine;

6-(tert-butylsulfonyl)-N-(5-fluoro-1*H*-indazol-3-yl)-7-(trifluoromethyl) quinolin-4-amine;

6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methylquinolin-4-amine;

6-(tert-butylsulfonyl)-N-(5-fluoro-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;

6-(tert-butylsulfonyl)-N-(5-fluoro-1*H*-indazol-3-yl)-7-methoxyquinolin-4-amine;

6-(tert-butylsulfonyl)-7-chloro-N-(5-fluoro-1*H*-indazol-3-yl)quinolin-4-amine;

6-(tert-butylsulfonyl)-7-ethyl-N-(5-fluoro-1*H*-indazol-3-yl)quinolin-4-amine;

N-(5-fluoro-1*H*-indazol-3-yl)-6-(isopropylsulfonyl)-7-methylquinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-(isopropylsulfonyl)-7-methylquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-ethylquinolin-4-amine;
7-ethyl-N-(5-fluoro-1*H*-indazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-ethyl-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
(3-((6-(tert-butylsulfonyl)-7-methoxyquinolin-4-yl)amino)-4-methylphenyl)methanol;
7-ethoxy-N-(5-fluoro-1*H*-indazol-3-yl)-6-(isopropylsulfonyl)quinolin-4-amine;
N-(7-chloro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
6-(tert-butylsulfonyl)-N-(7-fluoro-1*H*-indazol-3-yl)-7-methoxyquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(5,7-difluoro-1*H*-indazol-3-yl)-7-methoxyquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(6,7-difluoro-1*H*-indazol-3-yl)-7-methoxyquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(7-chloro-1*H*-indazol-3-yl)-7-methoxyquinolin-4-amine;
6-(tert-butylsulfonyl)-7-methoxy-N-(5-methoxy-1*H*-indazol-3-yl)quinolin-4-amine;
6-(tert-butylsulfonyl)-N-(7-fluoro-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(5,7-difluoro-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(5-methoxy-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(6,7-difluoro-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;
6-(tert-butylsulfonyl)-N-(7-chloro-1*H*-indazol-3-yl)-7-methylquinolin-4-amine;
7-methoxy-N-(4-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(5,7-difluoro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(4-chloro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(6-chloro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(6,7-difluoro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
7-methoxy-N-(5-methoxy-1*H*-indazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(5-chloro-1*H*-indazol-3-yl)-7-methoxy-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;
N-(7-chloro-1*H*-indazol-3-yl)-7-methoxy-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-1,3-benzothiazol-5-yl-6-(methylsulfonyl)-4-quinolinamine;

7-bromo-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

7-bromo-6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)quinolin-4-amine;

7-bromo-N-(4-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

7-bromo-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-(isopropylsulfonyl)quinolin-4-amine;

7-bromo-N-(5-fluoro-1*H*-indazol-3-yl)-6-(isopropylsulfonyl)quinolin-4-amine;

7-bromo-N-(5-fluoro-1*H*-indazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-7-(methyloxy)-4-quinolinamine;

6-(tert-butylsulfonyl)-4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)quinolin-7-ol;

2-((6-(tert-butylsulfonyl)-4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)quinolin-7-yl)oxy)ethanol;

6-(tert-butylsulfonyl)-7-(difluoromethoxy)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl) quinolin-4-amine;

7-(difluoromethoxy)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-((tetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)ethanol;

(3-((6-(tert-butylsulfonyl)-7-methoxyquinolin-4-yl)amino)-4-methyl-1*H*-pyrazol-5-yl)methanol;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methyl-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-(5-fluoro-1*H*-indazol-3-yl)-7-methyl-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-ethyl-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

7-ethyl-N-(5-fluoro-1*H*-indazol-3-yl)-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

N-(7-chloro-1*H*-indazol-3-yl)-7-methyl-6-((4-methyltetrahydro-2*H*-pyran-4-yl)sulfonyl)quinolin-4-amine;

or a salt thereof.

29. A compound which is 6-(tert-butylsulfonyl)-N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxyquinolin-4-amine or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising the compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

31. A method inhibiting RIP2 kinase which comprises contacting a cell with the compound or salt according to any one of claims 1-29.

32. A method of treating a RIP2 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of the compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

33. A pharmaceutical composition for the treatment of a RIP2 kinase-mediated disease or disorder, said composition comprising the compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


34. A compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, for use in therapy.

35. A compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, for use in the treatment of a RIP2 kinase-mediated disease or disorder.

36. The use of a compound according to any one of claims 1-29, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a RIP2 kinase-mediated disease or disorder.

CLAIMS

1. A compound according to Formula (I):



(I)

wherein:

R^1 is H, $-SO_2(C_1-C_4alkyl)$, $-CO(C_1-C_4alkyl)$, or (C_1-C_4alkyl);

R^2 is $-SOR^a$ or $-SO_2R^a$, wherein R^a is an optionally substituted (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl group, wherein:


said (C_1-C_6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, (C_1-C_6)alkoxy, (C_1-C_6)alkoxy(C_2-C_6)alkoxy, $-CO_2H$, $-CO_2(C_1-C_4)$alkyl, $-SO_2(C_1-C_4$ alkyl), $-CONH_2$, $-CONH(C_1-C_4$ alkyl), $-NHC(=O)(C_1-C_4$ alkyl), $-CON(C_1-C_4$ alkyl$)(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl$)(C(=O)(C_1-C_4$ alkyl)), $-SO_2NH_2$, $-SO_2NH(C_1-C_4$ alkyl), $-NHSO_2(C_1-C_4$ alkyl), $-SO_2N(C_1-C_4$ alkyl$)(C_1-C_4$ alkyl), - $N(C_1-C_4$ alkyl$)(SO_2(C_1-C_4$ alkyl)), amino, $(C_1-C_4$ alkyl)amino-, $(C_1-C_4$ alkyl$)(C_1-C_4$ alkyl)amino-, C_3-C_7cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and (phenyl)$(C_1-C_4$ alkyl)amino-, wherein said C_3-C_7cycloalkyl, phenyl, (phenyl)$(C_1-C_4$ alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-CF_3$, (C_1-C_4)alkyl, hydroxy(C_1-C_4)alkyl and (C_1-C_4)alkoxy,

said (C_3-C_7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-CF_3$, hydroxyl, amino, $(C_1-C_4$ alkyl)amino-, $(C_1-C_4$ alkyl$)(C_1-C_4$ alkyl)amino-, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl-, oxo, (C_1-C_4)alkoxy, and (C_1-C_4)alkoxy(C_2-C_4)alkoxy-, and

said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-CF_3$, hydroxyl, amino, (C_1-C_4)alkyl, phenyl(C_1-C_4)alkyl-, hydroxy(C_1-C_4)alkyl- and (C_1-C_4)alkoxy,

and wherein said heteroaryl is a 5-6 membered heteroaryl or a 9-10 membered heteroaryl, and any of said 4-7 membered heterocycloalkyl contains one heteroatom selected from the group consisting of N, O and S, any of said 5-6 membered heteroaryl contains one heteroatom selected from the group consisting of N, O and S and optionally further containing one or two nitrogen atoms, and any of said 9-10 membered heteroaryl contains one heteroatom selected from the group consisting of N, O and S and optionally further containing 1, 2 or 3 nitrogen atoms;

R^3 is halogen, hydroxy, (C_1-C_4)alkoxy-, halo(C_1-C_4)alkyl-, halo(C_1-C_4)alkoxy-, (C_1-C_4)alkoxy(C_1-C_6)alkyl-, halo(C_1-C_4)alkoxy(C_1-C_6)alkyl-, (C_1-C_4)alkoxy(C_2-C_6)alkoxy-, halo(C_1-C_4)alkoxy(C_2-C_6)alkoxy-, hydroxy(C_1-C_4)alkyl-, hydroxy(C_2-C_6)alkoxy-, cyano(C_1-C_4)alkyl-, cyano(C_2-C_6)alkoxy-, or (C_3-C_6)cycloalkoxy-, wherein the halo(C_1-C_4)alkyl-, halo(C_1-C_4)alkoxy-, halo(C_1-C_4)alkoxy(C_1-C_6)alkyl-, or halo(C_1-C_4)alkoxy(C_2-C_6)alkoxy- contains 2 or 3 halo atoms and wherein the (C_3-C_6)cycloalkyl moiety of the (C_3-C_6)cycloalkoxy- group, is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (C_1-C_6)alkoxy and (C_1-C_4)alkoxy(C_2-C_6)alkoxy;

Z is pyrazolyl, having the formula:  wherein:

R^{12} is methyl or trifluoromethyl ($-CH_3$ or $-CF_3$);

R^{13} is H, methyl, hydroxymethyl, or trifluoromethyl ($-CH_3$, $-CH_2OH$ or $-CF_3$);

R^{14} is H or (C_1-C_3)alkyl; or

R^{12} and R^{13}, taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R^{15} and R^{16}, wherein the heterocyclic ring contains 1 nitrogen atom;

wherein R^{15} and R^{16} are each independently selected from the group consisting of H, halogen, cyano, (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, (C_1-C_4)alkoxy, phenoxy, phenyl(C_1-C_4)alkoxy, hydroxyl, hydroxy(C_1-C_4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy

or phenyl(C_1-C_4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF_3, (C_1-C_4)alkyl and (C_1-C_4)alkoxy;


or a salt thereof.

2. The compound or salt according to claim 1, wherein R^1 is H.

3. The compound or salt according to claim 1, wherein R^2 is -SO_2R^a.

4. The compound, or salt thereof, according to claim 1, wherein the salt is a pharmaceutically acceptable salt of said compound.

5. A compound which is:



or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 4, and a pharmaceutically acceptable excipient.

7. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 5, and a pharmaceutically acceptable excipient.